Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~14 mi. (Nürnberg, Germany, +226 more cities)

Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~16 mi. (Erlangen, Germany, +192 more cities)

Universitätsklinikum Erlangen

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~16 mi. (Erlangen, Germany, +207 more cities)

Universitaetsklinikum Erlangen ( Site 1001)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~16 mi. (Erlangen, Germany, +159 more cities)

Universitaetsklinikum Erlangen ( Site 0505)

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

~16 mi. (Erlangen, Germany, +94 more cities)

Universitätsklinik Erlangen

HER2 Negative

Breast Carcinoma

sacituzumab govitecan

chemotherapy, +1 more type

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

~16 mi. (Erlangen, Germany, +145 more cities)

Universitaetsklinikum Erlangen ( Site 1209)

Non-Small Cell Lung Carcinoma

pembrolizumab, +1 more drug

immunotherapy, +2 more types

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

~16 mi. (Erlangen, Germany, +37 more cities)

Universitatsklinikum Erlangen

ER Negative, +2 more biomarkers

Breast Carcinoma

ladiratuzumab vedotin, +1 more drug

chemotherapy, +2 more types

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

~16 mi. (Erlangen, Germany, +17 more cities)

Universitätsklinikum Erlangen

ER Positive, +1 more biomarker

Invasive Breast Carcinoma

imlunestrant

hormone therapy

Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma

~16 mi. (Erlangen, Germany, +6 more cities)

University Hospital Department of Ophtalmology

Monosomy 3

Uveal Melanoma

therapeutic autologous dendritic cells

cellular therapy, +1 more type

Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy

~16 mi. (Erlangen, Germany)

University Hospital

Melanoma

dacarbazine

chemotherapy

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~28 mi. (Frankfurt, Germany, +199 more cities)

Universitaetsklinikum Frankfurt ( Site 0467)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~28 mi. (Frankfurt, Germany, +150 more cities)

Universitaetsklinikum Frankfurt ( Site 0403)

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types